Arcus Biosciences, Inc. [RCUS] faced a significant market correction after announcing the termination of its STAR-221 phase III trial, which had been developed in partnership with Gilead Sciences, Inc. [GILD]. The stock tumbled 14.4% on the news, though year-to-date performance remained solid at 44.